Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 3/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19155877 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CA1CNR1CNR2P2RX7 | |
| SCHEMBL3647113 | 0.73 | CASP2 (0.46) | ALDH1A1CNR1PSMB5 | |
| SCHEMBL20016486 | 0.73 | ALDH1A1 (0.41) | ALDH1A1CA1ANPEPRNPEPDNPEP | |
| SCHEMBL2633665 | 0.72 | ALDH1A1 (0.44) | ALDH1A1CA1CNR1CNR2P2RX7 | |
| SCHEMBL21578559 | 0.71 | — | — | |
| SCHEMBL6377554 | 0.71 | ALDH1A1 (0.38) | ALDH1A1CNR1CNR2LMNAPKM | |
| SCHEMBL25129079 | 0.70 | ALDH1A1 (0.39) | ALDH1A1CA1CNR1CNR2P2RX7 | |
| SCHEMBL24234910 | 0.69 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL25129044 | 0.69 | ALDH1A1 (0.38) | ALDH1A1CA1CNR1CNR2P2RX7 | |
| SCHEMBL23626511 | 0.69 | ANPEP (0.41) | ALDH1A1CA1ANPEPRNPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-10793862-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200123551-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, FUT6, GALNT13 | ALDH1A1 669/4885CA1 2100/4885CNR1 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.